Introduction {#s1}
============

*Staphylococcus aureus* is a versatile, opportunistic pathogen able to cause a wide range of diseases in humans, from minor skin infections to severe illnesses such as septicaemia, toxic shock, endocarditis and pneumonia. It is also able to colonize and infect a variety of other host species, including farm and companion animals and wildlife. The emergence and dissemination of methicillin-resistant *S. aureus* (MRSA) since the early 1960s has posed a major challenge to the treatment of *S. aureus* infections. Methicillin resistance in *S. aureus* is conferred by the acquisition of one of several staphylococcal cassette chromosome *mec* (SCC*mec*) elements, which carry the *mecA* gene encoding a penicillin-binding protein homologue (PBP2a) with reduced affinity for β-lactam antibiotics.^[@DKT462C1]^ We identified a novel *mecA* homologue, *mecA*~LGA251~, encoded in a new SCC*mec* element, designated type XI, among human and bovine MRSA isolates in the UK and Denmark.^[@DKT462C2]^ This *mecA* homologue, subsequently named *mecC*,^[@DKT462C1]^ exhibits only 69% identity at the DNA level and 63% identity at the protein level to the previously described *mecA*/PBP2a. As a result, it is not detectable by routine *mecA*-specific PCR approaches or PBP2a slide agglutination tests. *mecC* MRSA have now been isolated in small numbers from humans and a wide range of other host species in several European countries: Republic of Ireland,^[@DKT462C3]^ France,^[@DKT462C4]^ Sweden,^[@DKT462C5]--[@DKT462C7]^ the Netherlands,^[@DKT462C8]^ Germany,^[@DKT462C8]--[@DKT462C11]^ Austria,^[@DKT462C12]^ Switzerland,^[@DKT462C13]^ Finland,^[@DKT462C14]^ Spain,^[@DKT462C15]^ Norway^[@DKT462C16]^ and Belgium.^[@DKT462C17],[@DKT462C18]^ However, the origin and epidemiology of these strains are poorly understood and there are limited data on their prevalence. Importantly, the frequency of *mecC* MRSA has increased significantly in Denmark since 2003.^[@DKT462C19]^

To provide baseline data for future surveillance in the UK, we undertook a prospective survey of a total of 2010 MRSA isolates collected from six clinical microbiology laboratories in England and screened these by PCR or genome sequencing for *mecA* and *mecC*.

Methods {#s2}
=======

Isolate collection and assessment of mec gene status {#s2a}
----------------------------------------------------

Three hundred and thirty-five sequential MRSA isolates from individual patients were identified according to local procedures from screening and clinical samples at five hospital clinical microbiology laboratories from October 2011 to August 2012 (Table [1](#DKT462TB1){ref-type="table"}). These were sent to Cambridge for PCR detection of *mecA* and *mecC*, as described previously.^[@DKT462C17]^ These were isolates drawn from hospitals and other healthcare providers in the catchment area of each laboratory, including community-based general practitioners. Methicillin resistance was based on phenotypic resistance (cefoxitin disc diffusion, Vitek 2 or chromogenic agars) in all cases and not on molecular detection of *mecA* or PBP2a. Isolates from a sixth hospital (Addenbrooke\'s Hospital, Cambridge; Table [1](#DKT462TB1){ref-type="table"}) were collected as above and genome sequenced as part of an independent study. These were not assessed by PCR but by interrogation of their genome sequences using BLAST analysis to identify *mecA* and *mecC* MRSA isolates with confirmation of the presence of *femB* as a species marker of *S. aureus*. The analysis of 2010 isolates provides the power to detect *mecC* MRSA prevalence at a lower limit of 0.05% at the 95% confidence level. Table 1.Contributing hospitalsClinical microbiology laboratoryLocation (city and county)First sample dateLast sample dateNumber of *mecA*:*mecC* MRSARoyal Preston HospitalPreston, LancashireOctober 2011June 2012335 : 0Countess of Chester HospitalChester, CheshireNovember 2011August 2012335 : 0Nottingham Universities HospitalsNottingham, NottinghamshireJanuary 2012May 2012333 : 2Musgrove HospitalTaunton, SomersetNovember 2011May 2012333 : 2Royal Cornwall Hospitals TrustTruro, CornwallNovember 2011July 2012333 : 2Addenbrooke\'s HospitalCambridge, CambridgeshireApril 2012June 2012332 : 3

Antimicrobial susceptibility testing and slide agglutination for PBP2a {#s2b}
----------------------------------------------------------------------

All *mecC* MRSA isolates were analysed using the Vitek 2 system (bioMérieux, Basingstoke, UK). In brief, suspensions of cultures were made in 0.45% sodium solution from growth on Columbia blood agar, adjusted to a turbidity equivalent to that of a 0.5 McFarland standard and used to load the test cards, which were used in accordance with the manufacturer\'s instructions. The Staph AST-P620 card was automatically filled, sealed and inserted into the Vitek 2 reader--incubator module (incubation temperature 37°C), and fluorescence measurements were performed every 15 min for up to 18 h. Cefoxitin and oxacillin resistances were also assayed by disc diffusion following BSAC guidelines (version 11.1 May 2012) and the MICs of cefoxitin and oxacillin were determined using Etest strips (bioMérieux). All *mecC* MRSA isolates identified were tested with three commercially available PBP2a detection assays according to the manufacturers\' instructions: the Mastalex™ MRSA Test (Mast Diagnostics, Bootle, UK), the Penicillin Binding Protein (PBP2′) Latex Agglutination Test (Oxoid, Basingstoke, UK) and the Alere™ PBP2a Culture Colony Test (Alere Ltd, Stockport, UK). The *mecA*-positive MRSA strain NCTC12493 was used as a positive control.

Genome sequencing and spa typing {#s2c}
--------------------------------

All *mecC* MRSA isolates underwent whole genome sequencing using the HiSeq2000 platform (Illumina, Little Chesterford, UK) to confirm their *mecC* gene status and determine their multilocus sequence type (ST). Isolates that were PCR negative for either *mecA* or *mecC* were also genome sequenced to confirm their *mec* gene status. The species identity of isolates negative by PCR for *femB* was tested by assessing their growth and morphology on Staph Brilliance 24 and MRSA Brilliance 2 agar plates (both Oxoid) and by PCR to detect *nuc*.^[@DKT462C20]^ *spa* typing was performed using the primers spa-1113f (5′-TAA AGA CGA TCC TTC GGT GAG C-3′) and spa-1514r (5′-CAG CAG TAG TGC CGT TTG CTT-3′) as described by Ridom GmbH (Würzburg, Germany).

Results and discussion {#s3}
======================

PCR (or genome sequence analysis in the case of Addenbrooke\'s Hospital, Cambridge) revealed that 9 isolates out of a total of 2010 MRSA collected were *mecC* MRSA. These *mecC* MRSA isolates were largely from screening samples (six isolates), but included three isolates from skin and soft tissue infections. The remaining MRSA isolates were all *mecA* positive, which provides a prevalence rate of *mecC* MRSA among all MRSA collected of 0.45% with a 95% CI of 0.24%--0.85%. All 2010 isolates were confirmed to be *S. aureus*. In the majority of cases this identification was based on the presence of *femB* as detected by PCR or genome sequencing. However, 12 out of the 1675 isolates (0.72%) tested by PCR for *femB* were negative for an amplicon and were instead confirmed to be *S. aureus* based on their growth on Staph Brilliance and MRSA Brilliance agar plates and all were positive for *nuc*. The basis for the negative *femB* PCR result is under investigation and may relate to divergence in the *femB* primer binding sites. Indeed, a small number of *S. aureus* isolates negative for *femB* using alternative PCR approaches have been reported previously.^[@DKT462C21],[@DKT462C22]^ Two isolates were negative by PCR for both *mecA* and *mecC*, but genome sequencing revealed that they were indeed *mecA* positive and carried previously described *mecA* genes (NCBI accession numbers FJ390057 and AF411935) with divergence in the primer binding sites used in this study.

Genome sequencing confirmed that each isolate positive for *mecC* by PCR encoded *mecC* within an SCC*mec* type XI. Multilocus ST derived from the genome sequences revealed five different STs among the nine isolates, including a novel ST, ST2574. Eight of the isolates belonged to clonal complex (CC) 130, with the remaining isolate belonging to ST425. Five *spa* types were represented: t843, t6220, t9280, t11702 and t11706 (Table [2](#DKT462TB2){ref-type="table"}). All *mecC* MRSA isolates were resistant to cefoxitin and oxacillin using BSAC guidelines for disc diffusion, while MICs varied from 8 to 32 mg/L for oxacillin and from 8 to 16 mg/L for cefoxitin (Table [2](#DKT462TB2){ref-type="table"}). Antimicrobial susceptibility testing using Vitek 2 revealed that resistance to non-β-lactam antibiotics was rare, the only example being a single isolate, Ta222, displaying resistance to erythromycin and inducible resistance to clindamycin (Table [2](#DKT462TB2){ref-type="table"}). All nine isolates displayed the unusual Vitek 2 resistance profile of being resistant to cefoxitin, but susceptible to oxacillin. This feature of *mecC* MRSA, likely caused by structural differences between the *mecA*- and *mecC*-encoded PBP2a,^[@DKT462C23]^ has been described previously and may be helpful in the identification of *mecC* MRSA isolates.^[@DKT462C24]^ The susceptibility to oxacillin seen using Vitek 2 is in disagreement with our oxacillin disc diffusion results. *mecC*-encoded PBP2a has been shown to be less stable at 37°C than at 30°C,^[@DKT462C23]^ which may explain this discrepancy, oxacillin disc diffusion being performed at 30°C, but Vitek 2 analysis at 37°C. Cefoxitin resistance is presumably still seen using Vitek 2, even at 37°C, because of the higher affinity *mecC*-encoded PBP2a has for cefoxitin versus oxacillin.^[@DKT462C23]^ All nine *mecC* MRSA isolates gave negative results when assayed with three different commercial PBP2a slide agglutination assays, confirming the difficulty of detecting *mecC* MRSA using this approach. Table 2.Characteristics of *mecC* MRSA isolatesIsolateHospitalSTCC*spa* typeVitek profile^a^Oxacillin MIC (mg/L)Cefoxitin MIC (mg/L)Site of isolationN35Nottingham130130t843benzylpenicillin, cefoxitin1616leg ulcerN147Nottingham130130t11702benzylpenicillin, cefoxitin248wound swabTr8Truro2573130t843benzylpenicillin, cefoxitin1612multisite screenTr34Truro1245130t11706benzylpenicillin, cefoxitin328multisite screenTa222Taunton425425t11706benzylpenicillin, cefoxitin, erythromycin, inducible resistance to clindamycin88groin screenTa320Taunton1245130t6220benzylpenicillin, cefoxitin3212toe woundCa155Cambridge1245130t6220benzylpenicillin, cefoxitin2412multisite screenCa226Cambridge2574 (new)130t9280benzylpenicillin, cefoxitin168multisite screenCa322Cambridge1245130t843benzylpenicillin, cefoxitin3212multisite screen[^1]

This is the first formal prospective prevalence study of *mecC* MRSA performed in the UK and these data provide a baseline prevalence for the future surveillance of *mecC* MRSA in England. Continued monitoring of *mecC* is potentially important given the increase in prevalence of *mecC* MRSA reported in Denmark.^[@DKT462C19]^ There are few other data on *mecC* MRSA prevalence elsewhere, but in Germany a large multicentre prospective study identified a single *mecC* isolate among 1604 tested in 2004--05 and again a single isolate from 1603 tested in 2010--11.^[@DKT462C10]^ This indicates a prevalence of 0.06% with no change between the study periods. In contrast, the prevalence in Denmark was both higher and increasing, rising from 1.91% in 2010 to 2.78% in 2011.^[@DKT462C19]^ A survey of 565 human MRSA isolates in Switzerland failed to find any *mecC* MRSA, indicating that the prevalence there is lower than in Denmark.^[@DKT462C13]^ Clearly, there are significant and as yet unexplained differences in *mecC* MRSA prevalence between different countries, and the recent increase reported in Denmark suggests that it would be prudent to monitor prevalence in the UK and elsewhere.

None of the hospitals used oxacillin to identify MRSA, which has been shown to be less reliable than cefoxitin for the detection of *mecC* MRSA.^[@DKT462C25]^ Nonetheless, it is possible that some *mecC* MRSA may have been missed during primary isolation. For instance, small numbers of *mecC* MRSA isolates grow poorly on MRSA-selective agars,^[@DKT462C9],[@DKT462C17]^ presumably due to their having low cefoxitin/oxacillin MIC values. An area for future study may be the comparison and standardization of primary isolation methods in relation to *mecC* MRSA.

The majority of *mecC* MRSA isolates found in our survey belonged to CC130, which agrees with the data of Garcia-Alvarez *et al*.^[@DKT462C2]^ showing that CC130 was the most common lineage among their retrospective testing for *mecC* MRSA among human isolates in the UK and Denmark. Both CC130 and ST425 are the predominant lineages among *mecC* MRSA isolates found not only in humans but also in other host species elsewhere, and genome sequencing has provided strong evidence of cross-species transmission of *mecC* MRSA between humans and livestock.^[@DKT462C26]^ Of the five *spa* types recovered in this study, neither t11702 nor t11706 appear to have been reported previously among *mecC* MRSA, whilst the other three, t843, t6220 and t9280, have.^[@DKT462C2],[@DKT462C27]^ There were multiple CCs belonging to the same *spa* type and multiple *spa* types within the same CC, illustrating the difficulty of inferring CC from *spa* type data.

As reported for *mecC* MRSA isolated elsewhere in Europe and from different host species,^[@DKT462C9],[@DKT462C11],[@DKT462C15],[@DKT462C17],[@DKT462C27]^ resistance to non-β lactam antibiotics was uncommon among these English *mecC* MRSA isolates.

The origins of *mecC* MRSA and SCC*mec* type XI are unclear, but *mecC* has also been detected in *Staphylococcus stepanovicii*,^[@DKT462C12]^ *Staphylococcus xylosus*^[@DKT462C28]^ and *Staphylococcus sciuri*.^[@DKT462C29]^ This suggests a possible origin for *mecC* in coagulase-negative staphylococci, as proposed for *mecA*,^[@DKT462C30],[@DKT462C31]^ and clinical microbiology laboratories should therefore be aware not only of *mecC* MRSA but of the possible occurrence of *mecC* in other pathogenic species of methicillin-resistant staphylococci.
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[^1]: ^a^Only resistances are shown. Resistance to benzylpenicillin, cefoxitin, oxacillin, ciprofloxacin, erythromycin, chloramphenicol, daptomycin, fusidic acid, gentamicin, linezolid, mupirocin, nitrofurantoin, rifampicin, teicoplanin, tetracycline, tigecycline, trimethoprim, vancomycin and clindamycin was tested for, as well as inducible resistance to clindamycin.
